Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low incidence of agvhd with ptcy, tacrolimus and post-engraftment low dose ATG-based GvHD prophylaxis in haplo-identical donor transplantation and establish of new predict score for grade II-iv agvhd

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJiong Hu

Discussion

Loading...

Member takes

Overview

Observational analysis showed lower incidence of graft-versus-host disease in hematological malignancies, indicating risk stratification may guide therapy effectiveness.

Key Points

  • The incidence of graft-versus-host disease was significantly reduced with the Ruijin protocol in hematological malignancies.
  • Anti-thymocyte globulin and tacrolimus use alongside post-transplantation cyclophosphamide led to favorable outcomes.
  • Receiver age and CD34+ cell dose were identified as independent predictors for grade II-IV aGvHD.
  • The developed Ruijin score effectively stratified patients into risk groups for aGvHD in haplo-identical transplantation.

Cite This Study

Jiong Hu (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86ehttps://doi.org/10.1182/blood-2025-4224
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment2025
  2. 2Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations
  3. 3Factors associated with acute and chronic graft-versus-host disease after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025
  4. 4Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types2025
  5. 5A decade of experience using <scp>ATG</scp> and <scp>PTCy</scp> for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation2025 · 7 citations